CL
AST

CSS LLC’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

CSS LLC’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-32,100
Closed -$114K – 722
2017
Q2 		$114K Buy
32,100
+18,100
+129% +$59.6K 0.01% 561
2017
Q1 		$48K Buy
+14,000
New +$54.4K ﹤0.01% 599

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CSS LLC's AST Position: Q4 2017 in Review

CSS LLC sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2017, closing a stake of 26,115 shares — an estimated $89K sold.

CSS LLC first reported a position in AST in Q1 2017 and held it in 3 quarters. The position peaked at $89K in Q3 2017. 75 funds tracked by Wall St. Rank hold AST as of Q4 2017.

  • CSS LLC reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2017 after selling out during the quarter.
  • CSS LLC sold 26,115 Asterias Biotherapeutics Inc. Series A shares in Q4 2017, an estimated $89K.
  • CSS LLC first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2017 and held it in 3 quarters.
  • CSS LLC's Asterias Biotherapeutics Inc. Series A position peaked at $89K in Q3 2017.
  • 75 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2017.

Based on CSS LLC's 13F filing for Q4 2017, filed 14 Feb 2018.